Benitec Biopharma announces common stock offering, no amount given

Benitec Biopharma (BNTC) announced that it has commenced an underwritten public offering of its common stock and intends to conduct a concurrent registered direct offering of its common stock with long-term investor Suvretta Capital. The offerings are expected to close on November 7, subject to customary closing conditions. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Leerink Partners, TD Cowen and Evercore ISI are acting as bookrunning managers for the proposed offering.